Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.
Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, Shenkier T, Scott DW, Gascoyne RD, Slack GW, Parsons C, Morris J, Pickles T, Connors JM, Savage KJ. Hapgood G, et al. J Clin Oncol. 2016 Jul 20;34(21):2493-500. doi: 10.1200/JCO.2015.65.4194. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269949
Defining the clonality of peripheral T cell lymphomas using RNA-seq.
Brown SD, Hapgood G, Steidl C, Weng AP, Savage KJ, Holt RA. Brown SD, et al. Among authors: hapgood g. Bioinformatics. 2017 Apr 15;33(8):1111-1115. doi: 10.1093/bioinformatics/btw810. Bioinformatics. 2017. PMID: 28003262 Free PMC article.
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.
Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ. Hapgood G, et al. Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. Br J Haematol. 2019. PMID: 30873584 Free PMC article. No abstract available.
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Among authors: hapgood g. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Tilly H, et al. Among authors: hapgood g. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164048
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. Lewis KL, et al. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5. J Clin Oncol. 2023. PMID: 37797284
37 results